RARE Daily

Synteract Launches Rare Disease Institute

February 28, 2020

Rare Daily Staff

Contract Research Organization Synteract said it has launched an institute to provide webinars, interactive discussions, videos, and industry literature to help people better understand issues surrounding the clinical development of rare disease therapies.

The Synteract Rare Disease Institute will cover a variety of topics including such things as patient perspectives, bioethics, regulatory requirements, customer engagement, patient advocacy, and more.

“Our goal has been to provide a comprehensive rare disease program that spans from disease indications, innovative delivery models, to patient perspectives,” said Derek Ansel, Synteract’s director of rare, orphan, and pediatrics, who leads the program. “The Synteract Rare Disease Institute gives our employees a foundation in rare disease development and encourages proactive understanding and exploration of this growing area of clinical research.”

Synteract specializes in rare disease clinical trials. It has conducted more than 175 trials in the past five years for orphan diseases across more than 50 indications.


Stay Connected

Sign up for updates straight to your inbox.